LeMaitre Q1 2025 Financial Results

Rhea-AI Summary

LeMaitre Vascular reported strong Q1 2025 financial results with sales reaching $59.9 million, up 12% (13% organic). The company achieved a gross margin of 69.2% and operating income of $12.6 million, up 6%. Earnings per share increased 10% to $0.48. Growth was driven by grafts (+17%) and carotid shunts (+14%), with EMEA sales up 18%. The company announced a $0.20 quarterly dividend and increased its 2025 guidance, now expecting sales of $245 million (+12%) and EPS of $2.16 (+12%). Notably, Artegraft received MDR CE Mark approval, enabling European market expansion. The company maintains a strong cash position of $302.5 million and has authorized a $75 million share repurchase program.

Positive

• Sales grew 12% to $59.9M with strong organic growth of 13%
• Gross margin improved to 69.2% (+60 bps) due to higher pricing and efficiencies
• Strong regional performance with EMEA sales up 18% and Americas up 11%
• Artegraft received MDR CE Mark approval, enabling European expansion
• Increased 2025 guidance: Sales to $245M (+12%) and EPS to $2.16 (+12%)
• Robust cash position of $302.5M, up $2.8M sequentially
• $75M share repurchase program authorized

Negative

• Operating expenses grew 16% due to personnel costs
• APAC sales growth limited to 3%
• Ended Elutia porcine patch distribution agreement ($5M in 2024 U.S. sales)

Insights

Financial Analyst

LeMaitre delivered strong Q1 results with 13% organic growth, improved margins, and raised 2025 guidance, while maintaining robust cash reserves of $302.5M for strategic opportunities.

LeMaitre Vascular's Q1 2025 results demonstrate impressive momentum across multiple fronts. Sales reached $59.9 million, reflecting 12% growth (13% organic), with particular strength in grafts (+17%) and carotid shunts (+14%). Geographic performance shows the company executing well globally, with EMEA leading at 18% growth, Americas at 11%, and APAC at 3%.

Profitability metrics reveal operational improvements, with gross margin expanding 60 basis points year-over-year to 69.2% due to higher selling prices and manufacturing efficiencies. While operating expenses grew 16% from personnel investments, operating income still increased 6% to $12.6 million, maintaining a 21% operating margin. Earnings per share grew 10% to $0.48.

The company's strategic position strengthened with two significant developments: Artegraft (LeMaitre's largest U.S. product with $37 million in 2024 sales) received its MDR CE Mark, enabling European expansion, while the company is ending its Elutia porcine patch distribution agreement (which generated $5 million in 2024 sales). The net effect of these changes appears positive for future growth.

Cash reserves increased $2.8 million sequentially to $302.5 million, providing substantial flexibility for potential acquisitions. Management's confidence is evident in their decision to increase full-year guidance - raising projected sales from $239 million to $245 million and organic growth from 10% to 13%. The $0.20 quarterly dividend and new $75 million share repurchase program further reinforce a shareholder-friendly approach.

The 24% operating margin guidance for both Q2 and full-year 2025 suggests improving operational leverage in coming quarters compared to Q1's 21% margin. With double-digit growth projections for both revenue (12%) and EPS (12%) for 2025, LeMaitre appears well-positioned to deliver strong financial performance through the remainder of the year.

BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance.

Q1 2025:

• Sales $59.9mm, +12% (+13% organic)
• Gross margin 69.2%, +60 bps
• Op. income $12.6mm, +6%
• Op. margin 21%
• Earnings per diluted share $0.48, +10%
• Cash up $2.8mm sequentially to $302.5mm

Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%.

Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies.

Operating income of $12.6mm was up 6% in Q1. Operating expenses grew 16% largely due to personnel expenses. The Company currently employs 164 sales representatives and 34 sales managers.

Artegraft received its MDR CE Mark on April 29, and the European launch will begin presently. Artegraft, a biologic graft used in AV access and peripheral bypass, is the Company’s largest U.S. product, with $37mm in U.S. sales in 2024.

The Company ended its Elutia (formerly known as Aziyo Biologics) porcine patch distribution agreement on April 30. U.S. hospital sales were $5.0mm in 2024.

Chairman/CEO George LeMaitre said, “Q1 sales momentum allows us to increase our 2025 reported ($245mm) and organic (+13%) sales guidance, up from prior guidance of $239mm and 10%. $303mm of cash also provides strategic optionality.”

Business Outlook

	Q2 2025 Guidance		Full Year Guidance
Sales	$61.5mm - $63.5mm (Mid: $62.5mm, +12%, +12% Org.)		$242mm - $249mm (Mid: $245mm, +12%, +13% Org.)
Gross Margin	69.5%		69.6%
Op. Income	$14.6mm - $16.0mm (Mid: $15.3mm, +7%)		$55.1mm - $60.3mm (Mid: $57.7mm, +10%)
Op. Margin (Mid)	24%		24%
EPS	$0.55 - $0.59 (Mid: $0.57, +10%)		$2.07 - $2.24 (Mid: $2.16, +12%)

Quarterly Dividend

On April 29, 2025, the Company's Board of Directors approved a quarterly dividend of $0.20/share of common stock. The dividend will be paid on May 29, 2025, to stockholders of record on May 15, 2025.

Share Repurchase Program

On February 18, 2025, the Company's Board of Directors authorized the repurchase of up to $75.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 17, 2026, unless extended by the Board.

Conference Call Reminder

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company's website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. For individuals unable to join the live conference call, a replay will be available on the Company's website.
  
A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

For more information about the Company, please visit www.lemaitre.com.

Use of Non-GAAP Financial Measures

LeMaitre management believes that in order to better understand the Company's short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, GAAP financial performance measures. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events. The Company refers to the calculation of non-GAAP sales growth percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events. The non-GAAP profitability metrics provided herein allow the company to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. The Company believes that the presentation of guidance described above for sales, operating income, and EPS provides an alternative and meaningful view of the Company’s profitability.

Forward-Looking Statements

The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, competition from other medical device companies and alternative medical technologies; our ability to source, acquire, and integrate acquisitions; our ability to increase the selling prices of our products; our ability to maintain historic levels of profit growth; our dependence on sole- or limited-source suppliers; our implementation of our new enterprise resource planning system; disruptions to our information technology systems or breaches of our information security systems; our ability to engage sales call points other than vascular surgeons; our ability to procure, process, and preserve human tissue and comply with relevant regulatory requirements; the impact of a disruption in our manufacturing facilities; our ability to navigate the risks inherent in operating internationally; our ability to transition to direct sales models in certain international territories; the status of our regulatory approvals and compliance with regulatory requirements to market and sell our products both domestically and internationally; the occurrence of litigation relating to product liability, employment matters, intellectual property, contract disputes, and other commercial matters; the occurrence of product defects or recalls; our ability to service and repurchase our debt; the dilutive effect of a conversion of our debt; our ability to navigate executive officer transitions and retain key personnel; our ability to protect our intellectual property; and volatility in the price of our common stock; and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands)
			March 31, 2025				December 31, 2024
			(unaudited)
Assets
Current assets:
	Cash and cash equivalents		$	25,340			$	25,610
	Short-term marketable securities			277,209				274,112
	Accounts receivable, net			35,112				30,063
	Inventory and other deferred costs			65,906				64,927
	Prepaid expenses and other current assets			4,546				7,480
Total current assets				408,113				402,192
Property and equipment, net				25,106				24,800
Right-of-use leased assets				16,233				16,768
Goodwill				65,945				65,945
Other intangibles, net				34,399				35,819
Deferred tax assets				1,037				1,425
Other assets				5,173				4,868
Total assets			$	556,006			$	551,817
Liabilities and stockholders' equity
Current liabilities:
	Accounts payable		$	2,181			$	1,761
	Accrued expenses			19,929				24,732
	Acquisition-related obligations			-				1,433
	Lease liabilities - short-term			2,635				2,681
Total current liabilities				24,745				30,607
Convertible senior notes, net				167,984				167,772
Lease liabilities - long-term				14,742				15,232
Deferred tax liabilities				88				85
Other long-term liabilities				875				831
Total liabilities				208,434				214,527
Stockholders' equity
	Common stock			242				242
	Additional paid-in capital			217,118				213,760
	Retained earnings			151,584				145,090
	Accumulated other comprehensive loss			(5,153	)			(6,184	)
	Treasury stock			(16,219	)			(15,618	)
Total stockholders' equity				347,572				337,290
Total liabilities and stockholders' equity			$	556,006			$	551,817

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(amounts in thousands, except per share amounts)
(unaudited)
		For the three months ended
		March 31, 2025				March 31, 2024
Net sales		$	59,871			$	53,478
Cost of sales			18,451				16,813
Gross profit			41,420				36,665
Operating expenses:
	Sales and marketing		14,212				11,686
	General and administrative		10,487				9,013
	Research and development		4,095				4,092
Total operating expenses			28,794				24,791
Income from operations			12,626				11,874
Other income (expense):
	Interest income		2,903				1,001
	Interest expense		(1,290	)			-
	Other income (loss), net		2				(78	)
Income before income taxes			14,241				12,797
Provision for income taxes			3,230				2,910
Net income		$	11,011			$	9,887
Earnings per share of common stock
	Basic	$	0.49			$	0.44
	Diluted	$	0.48			$	0.44
Weighted - average shares outstanding:
	Basic		22,570				22,365
	Diluted		22,899				22,570
Cash dividends declared per common share		$	0.20			$	0.16

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
SELECTED NET SALES INFORMATION
(amounts in thousands)
(unaudited)
		For the three months ended
		March 31, 2025						March 31, 2024
		$			%			$			%
Net Sales by Geography
	Americas	$	38,958		65	%		$	35,245		66	%
	Europe, Middle East and Africa		16,959		28	%			14,395		27	%
	Asia Pacific		3,954		7	%			3,838		7	%
Total Net Sales		$	59,871		100	%		$	53,478		100	%

LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
				For the three months ended
				March 31, 2025			March 31, 2024
Reconciliation between GAAP and Non-GAAP EBITDA
	Net income as reported			$ 11,011			$ 9,887
	Interest (income) expense, net			(1,613	)		(1,001	)
	Amortization and depreciation expense			2,552			2,382
	Provision for income taxes			3,230			2,910
	EBITDA			$ 15,180			$ 14,178
	EBITDA percentage increase						7%

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)
NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
Reconciliation between GAAP and Non-GAAP sales growth:
	For the three months ended March 31, 2025
		Net sales as reported		$	59,871
		Impact of currency exchange rate fluctuations			754
		Adjusted net sales						$		60,625
	For the three months ended March 31, 2024
		Net sales as reported		$	53,478
		Adjusted net sales						$		53,478
		Adjusted net sales increase for the three months ended March 31, 2025						$		7,147		13%
Reconciliation between GAAP and Non-GAAP projected sales growth:
	For the three months ending June 30, 2025
		Net sales per guidance (midpoint)		$	62,545
		Impact of currency exchange rate fluctuations			(838	)
		Adjusted projected net sales						$		61,707
	For the three months ended June 30, 2024
		Net sales as reported		$	55,849
		Net impact of divestitures excluding currency			(960	)
		Adjusted net sales						$		54,889
		Adjusted projected net sales increase for the three months ending June 30, 2025						$		6,818		12%
Reconciliation between GAAP and Non-GAAP projected sales growth:
	For the year ending December 31, 2025
		Net sales per guidance (midpoint)		$	245,496
		Impact of currency exchange rate fluctuations			(1,464	)
		Adjusted projected net sales						$		244,032
	For the year ended December 31, 2024
		Net sales as reported		$	219,863
		Net impact of divestitures excluding currency			(3,265	)
		Adjusted net sales						$		216,598
		Adjusted projected net sales increase for the year ending December 31, 2025						$		27,434		13%

CONTACT: 
Gregory Manker
Director of Business Development and Investor Relations
+1 781-362-1260 x 419
gmanker@lemaitre.com 

FAQ

What were LeMaitre's (LMAT) Q1 2025 earnings per share?

LeMaitre reported Q1 2025 earnings per diluted share of $0.48, representing a 10% increase from the previous year.

How much is LeMaitre's (LMAT) quarterly dividend for Q2 2025?

LeMaitre announced a quarterly dividend of $0.20 per share, payable on May 29, 2025, to stockholders of record on May 15, 2025.

What is LeMaitre's (LMAT) revenue guidance for 2025?

LeMaitre increased its 2025 revenue guidance to $242-249 million (midpoint $245 million), representing 12% growth, with 13% organic growth.

How much cash does LeMaitre (LMAT) have on its balance sheet?

LeMaitre reported a cash position of $302.5 million as of Q1 2025, an increase of $2.8 million from the previous quarter.

What is the size of LeMaitre's (LMAT) share repurchase program?

LeMaitre's Board authorized a $75 million share repurchase program on February 18, 2025, which will conclude on February 17, 2026, unless extended.